SoFi Technologies (SOFI) shares dropped 8% despite beating Q1 revenue estimates as Q2 guidance and full-year outlook disappointed Wall Street analysts.
Browsing: News
Tesla (TSLA) stock nudged higher after Elon Musk teased Optimus V3 as ‘special,’ but investors remain cautious amid heavy spending and mixed Q1 results.
Nvidia (NVDA) fell 3% on OpenAI revenue concerns, but is the AI chip sell-off overblown? Analysts say demand remains strong across the sector.
Ford (F) reports Q1 earnings Wednesday. Analysts project $1.3B operating profit on $42.7B sales amid aluminum supply constraints and tariff challenges.
SanDisk (SNDK) stock surged 7.8% after Seagate’s strong earnings calmed AI storage demand fears. SanDisk reports Q3 results April 30.
Avis Budget (CAR) shares dropped 17% after reporting Q1 loss of $8.01 per share, missing estimates and extending a 70% decline from its April highs.
Bloom Energy (BE) surges 17% premarket after crushing Q1 with 130% revenue growth, raising guidance, and securing a $335 RBC price target.
AstraZeneca (AZN) stock fell despite Q1 earnings beat with $15.29B revenue and $2.58 EPS. Analysts attribute the drop to momentum already priced in.
BYD stock jumped 3.9% after Q1 earnings beat lowered expectations, with overseas markets now accounting for 45% of vehicle deliveries.
Wall Street analysts weigh in on leading AI stocks: Nvidia (NVDA), Microsoft (MSFT), and Alphabet (GOOGL). Full breakdown of ratings and 2026 targets.
NXP Semiconductors (NXPI) shares jumped 17% after strong Q1 results and Q2 revenue guidance of $3.45B, beating Wall Street forecasts by 5%.
Goldman Sachs has blocked Anthropic’s Claude AI for Hong Kong staff after contract review, while other AI tools remain accessible. Details on regulatory scrutiny.
TotalEnergies (TTEF) shares jumped after posting $5.4B Q1 earnings, up 29% YoY. The company raised dividends 5.9% and doubled buybacks to $1.5B.
Visa (V) shares jumped 5% after crushing Q2 estimates with $3.31 EPS and $11.2B revenue. Stock rallied on strong growth and $20B buyback announcement.
GSK stock dropped 3% after Q1 earnings topped forecasts. Legal provisions accounted for half the beat. Shingrix surged 20% while full-year outlook stands.